Multiple Sclerosis, Relapsing-Remitting
Conditions
Keywords
Relapsing remitting multiple sclerosis, D-Aspartate, interferon beta-1a
Brief summary
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
Interventions
DIETARY_SUPPLEMENTD-aspartate
D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
DRUGPlacebo
Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
BIOLOGICALIFN beta-1a
IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
DRUGMethylprednisolone
Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
Sponsors
Merck KGaA, Darmstadt, Germany
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Participants with RR-MS, according to the revised McDonald Criteria (2010) * Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse * Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit * Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential * Participants willing and able to comply with the protocol for the total duration of the study * Participants able to understand the purposes and the risks of the study * Participants have signed the appropriate written informed consent form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities * For MS participants with relapse: * Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution * Relapse started within maximum 5 days before the inclusion in the study * MS participants without relapse with clinically stable RR-MS
Exclusion criteria
* Participants with diagnosis of primary progressive MS (PP-MS) * Participants have any disease other than MS that could better explain his/her signs and symptoms * Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke) * Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids) * Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months) * Participants who have received any corticosteroids therapy within 3 months prior to the screening * Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressive agents during the course of the study * Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit * Participants with history or currently active primary or secondary immunodeficiency * Participants with inadequate liver function, defined by alanine aminotransferase (ALT) \> 3 \* upper limit of normal (ULN), or alkaline phosphatase (AP) \> 2 \* ULN, or total bilirubin \> 2 \* ULN if associated with any elevation of ALT or AP * Participants with inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 \* lower limit of normal (LLN) * Participants with moderate to severe renal impairment * Participants unable to complete an magnetic resonance imaging (MRI) (contraindications for MRI include but are not restricted to weight \>=140 kilogram (kg), pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc) * Participants with contraindication to gadolinium (Gd) can be enrolled into the study but cannot receive Gd contrast dyes during their MRI scans * Participants receiving supplements that, in the Investigator's opinion, may affect the evaluation of fatigue * Participants with any known contraindications or hypersensitivity to D-aspartate or any excipient * Participants with any other significant disease that in the Investigator's opinion would impede study assessments or endanger the participant * Female participants with positive pregnancy test at baseline or participants with active project of pregnancy during the study * Participants with legal incapacity or limited legal capacity * Participants have participated in any other investigational study within 8 weeks before the screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 | Baseline, Week 8 | EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | At Week 8, 12 and 24 | The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome. |
| 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Week 8, 12 and 24 | The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome. |
| Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | At Week 8, 12 and 24 | Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome. |
| Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Week 8, 12 and 24 | Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome. |
| Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24 | Baseline, Week 12 and 24 | EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS). |
| Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Week 8, 12 and 24 | Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome. |
| Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8 | TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome. |
| Number of Treated Participants With Immune-metabolic Response of Lymphocytes | Baseline, Week 8 and 12 | Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported. |
| Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Week 8, 12 and 24 | MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome. |
Countries
Italy
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. | 5 |
| Placebo + IFN Beta-1a + Methylprednisolone Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. | 2 |
| Total | 7 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 |
Baseline characteristics
| Characteristic | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 2 Participants | 7 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 3 Participants | 2 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 2 |
| other Total, other adverse events | 3 / 5 | 2 / 2 |
| serious Total, serious adverse events | 0 / 5 | 0 / 2 |
Outcome results
Primary
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: Baseline, Week 8
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 | 1 Participants |
| Placebo + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 | 0 Participants |
Secondary
25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Time frame: At Week 8, 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 8 | 13.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 8 | 12.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 1: Week 8 | 12.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 2: Week 8 | 12.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 8 | 17.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 8 | 16.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 8 | 11.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 8 | 10.9 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 8 | 5.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 8 | 5.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 12 | 5.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 12 | 5.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 24 | 11.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 24 | 11.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 24 | 8.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 24 | 9.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 24 | 11.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 24 | 11.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 24 | 5.0 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 24 | 5.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 12 | 13.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 12 | 13.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 12 | 17.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 12 | 15.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 12 | 10.9 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 12 | 10.2 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 8 | 16.1 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 8 | 14.3 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 8 | 9.3 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 8 | 8.9 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 24 | 10.1 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 24 | 9.8 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 12 | 12.7 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 12 | 12.3 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 12 | 12.4 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 12 | 11.8 Seconds |
Secondary
9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 12: Non-Dominant hand | 22.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 8: Dominant hand | 22.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 8: Dominant hand | 21.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 1: Week 8: Dominant hand | 18.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 2: Week 8: Dominant hand | 17.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 8: Dominant hand | 19.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 8: Dominant hand | 16.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 8: Dominant hand | 17.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 8: Dominant hand | 17.2 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 8: Dominant hand | 22.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 8: Dominant hand | 25.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 8: Non-Dominant hand | 18.9 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 8: Non-Dominant hand | 19.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 8: Non-Dominant hand | 22.0 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 8: Non-Dominant hand | 20.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 12: Non-Dominant hand | 22.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 12: Non-Dominant hand | 19.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 12: Non-Dominant hand | 20.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 12: Dominant hand | 25.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 12: Non-Dominant hand | 17.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 12: Non-Dominant hand | 17.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 12: Non-Dominant hand | 22.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 12: Non-Dominant hand | 23.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 24: Non-Dominant hand | 22.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 24: Non-Dominant hand | 20.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 24: Non-Dominant hand | 20.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 24: Non-Dominant hand | 18.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 24: Non-Dominant hand | 18.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 24: Non-Dominant hand | 18.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 24: Non-Dominant hand | 25.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 24: Non-Dominant hand | 22.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 12: Dominant hand | 24.2 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 12: Dominant hand | 22.0 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 12: Dominant hand | 17.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 12: Dominant hand | 17.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 12: Dominant hand | 16.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 12: Dominant hand | 16.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 12: Dominant hand | 23.2 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 24: Dominant hand | 22.0 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 24: Dominant hand | 21.5 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 24: Dominant hand | 18.8 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 24: Dominant hand | 18.1 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 1: Week 24: Dominant hand | 17.2 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Trial 2: Week 24: Dominant hand | 16.7 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 1: Week 24: Dominant hand | 27.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Trial 2: Week 24: Dominant hand | 24.6 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 1: Week 8: Non-Dominant hand | 25.2 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Trial 2: Week 8: Non-Dominant hand | 25.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 1: Week 8: Non-Dominant hand | 18.9 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Trial 2: Week 8: Non-Dominant hand | 17.3 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 1: Week 8: Non-Dominant hand | 21.4 Seconds |
| D-aspartate + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Trial 2: Week 8: Non-Dominant hand | 20.7 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 8: Dominant hand | 17.5 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 8: Dominant hand | 17.2 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 8: Dominant hand | 31.9 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 8: Dominant hand | 9.5 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 12: Non-Dominant hand | 20.4 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 12: Non-Dominant hand | 24.5 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 12: Non-Dominant hand | 25.7 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 24: Dominant hand | 32.6 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 24: Dominant hand | 30.8 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 8: Non-Dominant hand | 19.5 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 8: Non-Dominant hand | 19.9 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 12: Dominant hand | 21.1 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 2: Week 12: Dominant hand | 17.9 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 12: Dominant hand | 31.6 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 12: Dominant hand | 29.8 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 8: Non-Dominant hand | 22.0 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 8: Non-Dominant hand | 21.1 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 1: Week 24: Non-Dominant hand | 24.1 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Trial 2: Week 24: Non-Dominant hand | 23.6 Seconds |
| Placebo + IFN Beta-1a + Methylprednisolone | 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Trial 1: Week 12: Non-Dominant hand | 20.6 Seconds |
Secondary
Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 1: Week 8 | 1.2 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 2: Week 8 | 2.6 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 3: Week 8 | 1.7 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 4: Week 8 | 1.1 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 5: Week 8 | 1 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 5: Week 12 | 1 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 1: Week 24 | 1.3 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 3: Week 24 | 2.8 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 4: Week 24 | 2 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 5: Week 24 | 1.1 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 1: Week 12 | 1.3 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 3: Week 12 | 2.6 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 4: Week 12 | 2 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 6: Week 8 | 4.3 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 7: Week 8 | 2.2 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 7: Week 24 | 3.3 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 6: Week 12 | 4.1 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24 | Participant 7: Week 12 | 4.1 units on a scale |
Secondary
Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.
Time frame: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8
Population: Full analysis set. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, Number of participants analyzed signifies those who were evaluated for this endpoint and number analyzed signifies specific participant evaluated in respective arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Baseline): 110% RMT | 30 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Baseline): 120% RMT | 105 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Baseline): 130% RMT | 142 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Post-baseline): 110% RMT | 39 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Post-baseline): 120% RMT | 128 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 1: Week 8 (Post-baseline): 130% RMT | 154 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Baseline): 110% RMT | 23 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Baseline): 120% RMT | 95 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Baseline): 130% RMT | 115 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Post-baseline): 110% RMT | 31 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Post-baseline): 120% RMT | 103 millivolts |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 3: Week 8 (Post-baseline): 130% RMT | 118 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Post-baseline): 130% RMT | 138 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Baseline): 110% RMT | 33 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Baseline): 110% RMT | 28 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Baseline): 120% RMT | 83 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Baseline): 130% RMT | 118 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Post-baseline): 110% RMT | 26 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Post-baseline): 120% RMT | 91 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 6: Week 8 (Post-baseline): 130% RMT | 125 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Baseline): 120% RMT | 140 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Baseline): 130% RMT | 149 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Post-baseline): 110% RMT | 30 millivolts |
| Placebo + IFN Beta-1a + Methylprednisolone | Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS) | Participants 7: Week 8 (Post-baseline): 120% RMT | 135 millivolts |
Secondary
Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Population: Full analysis set. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, Number of participants analyzed signifies those who were evaluable for this endpoint and number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 8: Left eye | 4 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Week 8: Left eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 8: Left eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 8: Left eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 8: Right eye | 4 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Week 8: Right eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 8: Right eye | 2 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 8: Right eye | 7 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 12: Right eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 12: Right eye | 10 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 12: Right eye | 7 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 24: Right eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 24: Right eye | 10 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 24: Right eye | 10 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 12: Left eye | 2 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 12: Left eye | 10 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 12: Left eye | 8 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 24: Left eye | 3 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 24: Left eye | 10 Letters read correctly |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 24: Left eye | 10 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 8: Left eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 8: Left eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 24: Left eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 8: Right eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 12: Right eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 12: Left eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 12: Left eye | 9 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 12: Right eye | 9 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 24: Right eye | 8 Letters read correctly |
| Placebo + IFN Beta-1a + Methylprednisolone | Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 8: Right eye | 8 Letters read correctly |
Secondary
Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 1: Week 8 | 8 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 2: Week 8 | 27 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 3: Week 8 | 15 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 4: Week 8 | 2 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 5: Week 8 | 18 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 5: Week 12 | 15 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 1: Week 24 | 10 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 3: Week 24 | 48 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 4: Week 24 | 12 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 5: Week 24 | 15 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 1: Week 12 | 6 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 3: Week 12 | 12 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 4: Week 12 | 12 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 6: Week 8 | 27 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 7: Week 8 | 29 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 7: Week 24 | 43 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 6: Week 12 | 27 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24 | Participant 7: Week 12 | 30 units on a scale |
Secondary
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: Baseline, Week 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24 | Week 12 | 1 Participants |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24 | Week 24 | 1 Participants |
| Placebo + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24 | Week 12 | 0 Participants |
| Placebo + IFN Beta-1a + Methylprednisolone | Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24 | Week 24 | 0 Participants |
Secondary
Number of Treated Participants With Immune-metabolic Response of Lymphocytes
Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.
Time frame: Baseline, Week 8 and 12
Population: Data was not collected since the study was prematurely terminated, due to slow recruitment rate.
Secondary
Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.
Time frame: At Week 8, 12 and 24
Population: Full analysis set included all participants enrolled into the study and assigned to the randomized treatment. No summary analysis was done as study was prematurely terminated due to slow recruitment rate and participant wise data are reported. Here, number analyzed signifies specific participant evaluated in respective arm at specified timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 24 | 70 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Week 24 | 39 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 12 | 44 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 12 | 68 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Week 12 | 44 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 24 | 50 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 24 | 51 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 8 | 38 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 2: Week 8 | 43 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 3: Week 8 | 48 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 4: Week 8 | 66 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 5: Week 8 | 46 units on a scale |
| D-aspartate + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 1: Week 12 | 48 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 24 | 55 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 12 | 43 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 8 | 56 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 7: Week 8 | 43 units on a scale |
| Placebo + IFN Beta-1a + Methylprednisolone | Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment | Participant 6: Week 12 | 46 units on a scale |